Verbatim response from ChatGPT
Short answer
- Many people see noticeable weight loss within weeks and 5–15% body-weight loss within 6–12 months on commonly used GLP‑1/GIP drugs. How fast you lose weight varies a lot by drug, dose, baseline weight, diet/exercise, and side effects.
- Weight loss is usually durable only while you keep taking the medication plus lifestyle changes. Stopping often leads to regain unless you have a solid, sustained behavioral plan.
Details — what to expect
- Early phase (first 4–12 weeks): appetite suppression and smaller meals cause fairly rapid initial losses for many people. Typical: 1–4 lb (0.5–2 kg) per month for some, faster for others. Nausea or reduced food intake can amplify early loss.
- 3–6 months: clinically meaningful weight loss is common — many people hit 5–10% body-weight loss in this window.
- 6–12 months: clinical trial averages depend on the drug and dose:
- Semaglutide 2.4 mg (Wegovy) produced roughly 10–15% average weight loss at ~68 weeks in trials.
- Tirzepatide (Zepbound for obesity; Mounjaro is the diabetes brand often used off‑label) produced larger average losses in trials (many participants lost ~15–20%+ at ~72 weeks at higher doses).
- Lower doses or oral semaglutide (Rybelsus) tend to give smaller average losses.
- Plateaus: weight loss typically slows or plateaus after several months as the body adapts.
Why results vary
- Dose and specific drug (tirzepatide generally shows larger losses than semaglutide in head‑to‑head trials).
- Starting weight/body composition (absolute kg lost tends to be higher when baseline weight is higher).
- How strictly diet and activity are changed and whether behavioral support is used.
- Side effects that limit dose escalation (some people stop uptitration because of nausea).
Sustainability
- GLP‑1/GIP medications change appetite and food reward, so most of their benefit depends on continuing the drug. Randomized trials and observational data show weight tends to be regained after stopping the drug unless other long‑term behavioral or surgical changes are in place.
- For many people these drugs become a long‑term therapy for weight management—similar to medications for blood pressure or diabetes.
- Combining medication with structured diet, exercise, and counseling improves chances of long‑term success and may reduce how much medication is needed over time, but continuing medication is often part of the maintenance strategy.
Risks, monitoring and practical points
- Common side effects: nausea, constipation/diarrhea, vomiting, reduced appetite. Less common but important risks: gallbladder disease, pancreatitis (rare), and thyroid‑cell tumor signal in rodents (human relevance uncertain). Discuss personal risks with your clinician.
- Cost/coverage varies: Wegovy, Zepbound, Mounjaro, Ozempic often have high out‑of‑pocket cost if insurance doesn’t cover obesity indication.
- You need a prescription and medical follow‑up to monitor side effects, dose, and blood tests as appropriate.
Brands to know (examples)
- Wegovy (semaglutide 2.4 mg) — approved for weight loss; strong evidence for ~10–15% average loss at ~1 year.
- Zepbound (tirzepatide) — approved for weight management; trials showed larger average weight loss (often >15%) at higher doses.
- Mounjaro (tirzepatide) — approved for type 2 diabetes; used off‑label for weight loss in some settings with similar efficacy to Zepbound in trials.
- Ozempic (semaglutide) — approved for diabetes; commonly used off‑label for weight loss but the labeled obesity dose is Wegovy.
- Rybelsus (oral semaglutide) — pill form, smaller average weight effects than injectable semaglutide at the obesity dose.
What I recommend you do next
- Talk with your primary care doctor, endocrinologist, or a weight‑management clinic to discuss whether a GLP‑1/GIP medicine suits you, your medical risks, and a monitoring plan.
- If you want, tell me your current weight/height, the drug you’re considering (or already on), and your timeline goals and I can give a rough estimate of expected weight change and a maintenance strategy.